Fairmont Empress Victoria Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

New Paradigms in Cancer Therapeutics (Z1)


Organizer(s) Arul M. Chinnaiyan and William R. Sellers
March 23—28, 2010
Fairmont Empress Victoria • Victoria, British Columbia Canada
Abstract Deadline: Nov 24, 2009
Late Abstract Deadline: Dec 29, 2009
Scholarship Deadline: Nov 24, 2009
Early Registration Deadline: Jan 25, 2010

Sponsored by Abbott Laboratories, Genentech BioOncology and sanofi-aventis


Summary of Meeting:
The advent of genome-scale profiling technologies has opened up the possibility of comprehensively monitoring multiple layers of molecular aberrations in cancer. Alterations in the epigenome, genome, transcriptome, proteome and metabolome have all been observed in tumor development. A number of key molecular pathways have been found to be altered during cancer progression. Pivotal questions in the field include: Can these novel pathways alone or in combination be effectively targeted in cancer? Can we identify molecular signatures that will facilitate personalized medicine? What are the innovative therapeutic modalities that can be employed to target these pathways? The goal of this meeting is to tackle promising new targets for cancer therapy. These include targets such as recurrent gene fusions, epigenetic pathways, and metabolic networks. We will also explore the use of molecular marker panels to select patients for treatment. A number of approaches to therapeutic targeting will be discussed including novel biologics and RNA interference.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, MARCH 23

15:00—19:30
Registration

Prefunction 2
18:30—19:30
Refreshments

Prefunction 2
19:30—20:30
Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

Salon B-C
Hans C. Clevers, Hubrecht Institute, Netherlands
Wnt, Lgr5 Stem Cells and Cancer


WEDNESDAY, MARCH 24

07:00—08:00
Breakfast

Palm Court
08:00—11:15
Epigenetic Targets in Cancer
Meeting has ended...abstracts no longer viewable online.

Salon B
* Arul M. Chinnaiyan, University of Michigan, USA

Patrick Trojer, Constellation Pharmaceuticals, USA
Targeting the Dynamics of Histone Lysine Methylation

Thea D. Tlsty, University of California, San Francisco, USA
Reprogramming the Epigenome during Cancer Progression

Peter A. Jones, Van Andel Research Institute, USA
Cancer Epigenomics

Jean-Pierre Issa, Temple University School of Medicine, USA
Combinations Targeting Multiple Epigenetic Pathways

Akihide Yoshimi, Graduate School of Medicine, University of Tokyo, Japan
Short Talk: EVI1 Induces a Novel Epigenetic Regulation of PTEN/AKT/mTOR Signaling through Interaction with Polycomb Complexes in Leukemia

Aliaksei Holik, Cardiff University, UK
Short Talk: Chromatin Remodelling ATPase Brg-1 is an Essential Factor for the Maintenance of the Intestinal Crypt Stem Cell and Wnt Driven Adenoma Formation

08:00—11:15
Integrating Signal Gradients in Development
Meeting has ended...abstracts no longer viewable online.
Hh vs. Wnt or TGFbeta, Notch, etc. in developing Neural Tube, Fly Wing Imaginal Disc., A/P or D/V Polarity etc.

Salon C
* Elaine V. Fuchs, HHMI/Rockefeller University, USA

Jean-Denis Benazet, University of Southern California, USA
Interlinked Signaling Feedback Loops and Self-Regulation during Mouse Limb Development

Xi He, Harvard Medical School, USA
Mechanisms of Wnt Signaling and Regulation

Chi-chung Hui, Hospital for Sick Children, Canada
Regulators of Gli Transcription Factors in Development and Cancer

Brandon J. Wainwright, University of Queensland, Australia
The Intersection between Hedgehog and Notch Signaling in Development and Cancer

Elizabeth Ann Grove, University of Chicago, USA
Signaling Gradients in Patterning the Mammalian Cerebral Cortex

09:20—09:40
Coffee Break

Prefunction 2
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Salon A
13:00—22:00
Poster Viewing

Salon A
16:30—17:00
Coffee Available

Prefunction 2
17:00—19:00
Predictive Signatures for Cancer
Meeting has ended...abstracts no longer viewable online.

Salon B
Levi A. Garraway, Eli Lilly and Company, USA
High-Throughput Oncogene Mutation Profiling in Human Cancer

Joe W. Gray, Oregon Health and Science University, USA
Omics Based Approaches to Predict Cancer Therapy

William R. Sellers, , USA
Connecting Patients to Therapy: Functional and Comparative Approaches to Translational Oncology

Daniel R. Rhodes, University of Michigan, USA
Short Talk: Somatic Mutations in Human Cancer Cell Lines Predict Sorafenib Response

17:00—19:00
Mechanisms of Signal Integration I - Hippo Pathway and Cilia
Meeting has ended...abstracts no longer viewable online.

Salon C
* Ken M. Cadigan, University of Michigan, USA

Jeremy F. Reiter, University of California, San Francisco, USA
Primary Cilia Transduce Hedgehog Signals in Both Development and Cancer

Elaine V. Fuchs, HHMI/Rockefeller University, USA
Developmental Signaling Pathways in the Skin

Helen McNeill, Lunenfeld-Tanenbaum Research Institute, Canada
Fat Cadherins in the Regulation of Growth and Planar Cell Polarity

Rhonda Hui Ping Kan, Institute for Molecular Bioscience, Australia
Short Talk: N-myc and C-myc are Functionally Redundant in Mediating the Effects of Ptch1 Mutation in Epidermis

19:00—20:00
Social Hour with Lite Bites

Salon A
19:30—22:00
Poster Session 1

Salon A

THURSDAY, MARCH 25

07:00—08:00
Breakfast

Palm Court
08:00—11:15
Targeting Developmental Pathways in Cancer (Joint)
Meeting has ended...abstracts no longer viewable online.

Salon B-C
* Marion Dorsch, Blueprint Medicines Corporation, USA
Hedgehog Inhibitors

A. Thomas Look, Dana-Farber Cancer Institute, USA
Activating Mutations in the ALK Tyrosine Kinase Provide a Therapeutic Target in Neuroblastoma

Luisa Iruela-Arispe, University of California, Los Angeles, USA
Angiogenesis, Developmental Pathways and Cancer

James F. Amatruda, University of Texas Southwestern Medical Center, USA
Short Talk: BMP Signaling in Germ Cell Differentiation and Germ Cell Tumors

Leni S. Jacob, Memorial Sloan-Kettering Cancer Center, USA
Short Talk: Assignment of Aberrant Hedgehog and Wnt Pathway Activity to Disease by Genome-Wide RNAi in Cultured Cells

09:20—09:40
Coffee Break

Prefunction 2
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Salon A
13:00—22:00
Poster Viewing

Salon A
16:30—17:00
Coffee Available

Prefunction 2
17:00—19:00
Recurrent Gene Fusions as Cancer Therapeutic Targets
Meeting has ended...abstracts no longer viewable online.

Salon B
* Levi A. Garraway, Eli Lilly and Company, USA

Hiroyuki Mano, University of Tokyo, Japan
Targeting the ALK Fusion Genes in Lung Cancer

Arul M. Chinnaiyan, University of Michigan, USA
Targeting Gene Fusions in Prostate Cancer

Yardena Samuels, Weizmann Institute of Science, Israel
Mutational Analysis of the Melanoma Genome

Yoshihiro Yamashita, University of Tokyo, Japan
Short Talk: Array-based Genomic Resequencing of Acute Myeloid Leukemia

17:00—19:00
Mechanisms of Signal Integration II - Coordinated Proteolysis
Meeting has ended...abstracts no longer viewable online.

Salon C
* Xi He, Harvard Medical School, USA

Randall T. Moon, University of Washington School of Medicine, USA
Elucidating Wnt/beta-Catenin Signaling Networks by Integrated siRNA, Proteomic, and Small Molecule Screens

Jin Jiang, University of Texas Southwestern Medical Center, USA
Kinase Regulation of Hedgehog Signaling

Ying E. Zhang, NCI, National Institutes of Health, USA
Proteolysis in TGF-beta Signaling and Cancer

Masahiro Narimatsu, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Canada
Short Talk: Smurf Ubiqutin Ligases are Required for Embryo Patterning during Gastrulation

19:00—20:00
Social Hour with Lite Bites

Salon A
19:30—22:00
Poster Session 2

Salon A

FRIDAY, MARCH 26

07:00—08:00
Breakfast

Palm Court
08:00—11:00
Toward Rational Targeted Combination Therapy
Meeting has ended...abstracts no longer viewable online.

Salon B
* Arul M. Chinnaiyan, University of Michigan, USA

Kenneth P. Nephew, Indiana University, USA
DNA Methylation Inhibitors for Chemotherapy Resensitization of Solid Tumors

Paul G. Polakis, Genentech, Inc., USA
Wnt Antagonists in Cancer

Shaomeng Wang, University of Michigan, USA
Current Targeting of Multiple Key Apoptosis Regulators is Required to Efficiently Kill Tumor Cells

Caroline M. Emery, Dana Farber Cancer Institute, USA
Short Talk: Genetic Studies of Resistance to MEK and BRAF Inhibition

Jinyan Du, Merrimack Pharmaceuticals, USA
Short Talk: Systematic Characterization of Pathway Interactions with ER Signaling in Human Mammary Carcinomas

08:00—11:00
Mechanisms of Integration III - Transcriptional Regulation and/or Epigenetics/Reversible Histone Methylation
Meeting has ended...abstracts no longer viewable online.

Salon C
* Austin Smith, University of Cambridge, UK

Michael D. Taylor, Hospital for Sick Children, Canada
A Role for Histone Lysine Methylation in the Pathogenesis of Pediatric Brain Tumors?

Marion Dorsch, Blueprint Medicines Corporation, USA
Smoothened Antagonists: Anticipating and Treating Resistance

Ken M. Cadigan, University of Michigan, USA
Selection of Wnt Targets and Subsequent Chromatin Modifications

Feng Cong, Novartis Institutes for BioMedical Research, USA
Short Talk: Targeting Wnt Signaling through TNKS Inhibition and Axin Stabilization

Felix Lohmann, Novartis Institutes for BioMedical Research, Switzerland
Short Talk: KMT1E Mediated H3K9 Methylation is Required for the Maintenance of Embryonic Stem Cells by Repressing Trophectoderm Differentiation

Robert Rottapel, Princess Margaret Hospital, Toronto Medical Discovery Tower, Canada
Short Talk: Tankyrase Functions as a Cross-Regulator of Signalling Pathways

09:20—09:40
Coffee Break

Prefunction 2
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Prefunction 2
17:00—19:00
Targeting Metabolic Pathways in Cancer
Meeting has ended...abstracts no longer viewable online.

Salon B
* Luisa Iruela-Arispe, University of California, Los Angeles, USA

Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA
Targeting Cancer Cell Metabolism

Valeria Fantin, ORIC Pharmaceuticals, USA
Cancer-Associated IDH1 Mutations Produce 2-Hydroyxglutarate

Patrick S. Ward, Massachusetts General Hospital, USA
Short Talk: The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations is a Neomorphic Enzyme Activity Converting alpha-Ketoglutarate to 2-Hydroxyglutarate

Amjad Pervez Khan, University of Michigan, USA
Short Talk: Metabolomic Profiling Delineate Polyamines as Biomarkers for Prostate Cancer Progression

17:00—19:00
Stem Cell Fate and Signaling
Meeting has ended...abstracts no longer viewable online.

Salon C
* Morag Park, McGill University, Canada

Jim Woodgett, Mount Sinai Hospital, Canada
Coordinate Regulation of Multiple Signaling Pathways and Differentiation Processes by Glycogen Synthase Kinase-3

Austin Smith, University of Cambridge, UK
Intrinsic and Extrinsic Regulation of the Pluripotent Ground State

Jeffrey L. Wrana, Mount Sinai Hospital, Canada
Cell Fate and Polarity Signals

Rita Lukacs, Takeda California, USA
Short Talk: Bmi-1 is a Dominant Self-Renewal Gene in the Murine Prostate that Controls both Stem Cell Maintenance and Cancer Initiation

19:00—20:00
Social Hour with Lite Bites

Salon A

SATURDAY, MARCH 27

07:00—08:00
Breakfast

Palm Court
08:00—11:00
siRNA Therapeutics
Meeting has ended...abstracts no longer viewable online.

Salon B
* William R. Sellers, , USA

Daniel G. Anderson, Massachusetts Institute of Technology, USA
Combinatorial Development of Biomaterials and Synthetic siRNA Delivery Systems

Ian MacLachlan, Tekmira Pharmaceuticals Corp., Canada
Therapeutic Silencing of Polo-Like Kinase 1 and Kinesin Spindle Protein via the Confirmed Mechanism of RNA Interference

John J. Rossi, Beckman Research Institute of the City of Hope, USA
Strategies for RNA Interference (RNAi) Applications in Cancer Therapy

Eric Marcusson, Providence Therapeutics, USA
Short Talk: microRNA Mimics as Cancer Therapeutics

Steven Blake, University of North Carolina at Chapel Hill, USA
Short Talk: Targeted Delivery of siRNA using PRINT® Particles

Kathy L. Fosnaugh, Aminex Therapeutics, Inc., USA
Short Talk: Development of siRNA Therapeutics for Treatment of Bladder Cancer and Hepatocellular Carcinoma

08:00—11:00
Integrated Signaling in Tumor/Stromal Interaction
Meeting has ended...abstracts no longer viewable online.
Emerging stories around tumors and stroma feeding each other signals and each changing to reinforce cancer.

Salon C
* Jeffrey L. Wrana, Mount Sinai Hospital, Canada

Morag Park, McGill University, Canada
Breast Tumor Microenvironment: Impact on Tumor Heterogeneity and Outcome

John Condeelis, Albert Einstein College of Medicine, USA
The Tumor Microenvironment Invasion Signature: Effects on Tumor Cell Plasticity in vivo

Christine Dierks-Ventling, Friedrich Miescher Institut, Switzerland
Hedgehog Signaling in Hematologic Malignancies

Minoti Apte, University of New South Wales, Australia
Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells

Gabri Van der Pluijm, Leiden University Medical Center, Netherlands
Short Talk: TGFbeta-BMP7 Interactions in Bone Metastasis; Potential Therapeutic Implications

09:20—09:40
Coffee Break

Prefunction 2
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Prefunction 2
17:00—19:00
Novel Biologic and Virus Based Cancer Therapeutics
Meeting has ended...abstracts no longer viewable online.

Salon B
* William R. Sellers, , USA

Serge Muyldermans, Vrije Universiteit Brussel, Belgium
Camelid Nanobodies for Cancer and Diagnostic Assay Development

Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Engaging T Cells for Cancer Therapy by Bispecific Antibodies

Sunjoo Jeong, Dankook University, South Korea
Short Talk: RNA Aptamers for the Modulation of Wnt/beta-catenin Signaling

Mohammad Qadir, BC Cancer Agency, Canada
Short Talk:

Sandra E. Dunn, University of British Columbia, Canada
Short Talk:

17:00—19:00
Aberrant Signal Interactions and Disease
Meeting has ended...abstracts no longer viewable online.

Salon C
* Jim Woodgett, Mount Sinai Hospital, Canada

Geraldine Weinmaster, David Geffen School of Medicine at UCLA, USA
Ligand Endocytosis and Force Generation in Activation of Notch Signaling

Bruce A. Edgar, German Cancer Research Center, Germany
Signaling and Stem Cell Control in the Drosophila Intestine

Adolfo Ferrando, Columbia University, USA
NOTCH1 Transcriptional Networks in Human Leukemia

Daniela F. Quail, McGill University, Canada
Short Talk: Nodal Promotes Metastasis and Stem Cell Phenotypes in Breast Cancer

19:00—20:00
Social Hour with Lite Bites

Palm Court
20:00—23:00
Entertainment

Palm Court

SUNDAY, MARCH 28

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA144367-01




We gratefully acknowledge additional support for this conference from:

Abbott Laboratories Cell Signaling Technology, Inc.
Exelixis, Inc. Genentech BioOncology
Sanofi US
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Micromet, Inc.


Novartis Institutes for BioMedical Research


Tekmira


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

ACS Publications

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676